Report : North America Enteral Medical Nutrition Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Indication (Respiratory Disorders, Cancer, Post COVID-19, Gastrointestinal Disorders, Liver Failure, and Others), Nutrition Type (Supplemental and Sole-Source), Form (Powder, Liquid, and Semi-Solid), Product (Standard Protein Diet, High Protein Diet, Fruit Juice Based Oral Nutritional Supplement, and Others), Distribution Channel (Hospital Pharmacies, Retail Stores, and Others), and Age Group [Child (Till 18 Years) and Adults (18+years)]
At 5.8% CAGR, the North America Enteral Medical Nutrition Market is speculated to be worth US$ 5,043.51 Million by 2028, says Business Market Insights
According to Business Market Insights’ research, the North America enteral medical nutrition market was valued at US$ 3,602.61 million in 2022 and is expected to reach US$ 5,043.51 million by 2028, registering an annual growth rate of 5.8% from 2022 to 2028. Increase in prevalence of cachexia and rise in prevalence of gastrointestinal diseases are the critical factors attributed to the market expansion.
Crohn’s disease, gastrointestinal disease due to trauma, bowel obstruction (BO), microscopic colitis, short bowel syndrome, and ulcerative colitis are a few gastrointestinal diseases. According to Medscape, in developed countries, the most common cause of small-bowel obstruction (SBO) is intra-abdominal adhesions, accounting for ~65 to 75% of cases, followed by hernias. In contrast, in developing countries, SBO is primarily caused by hernias (30–40%), adhesions (about 30%), and tuberculosis (about 10%).
Crohn’s disease is a complex, long-lasting (chronic) disorder that primarily affects the digestive system. It is most common disease in North America and has a prevalence of 100 to 300 per 100,000 in the region. According to Medline Plus, more than half a million in North American people are currently suffering from Crohn’s disease. Patients with gastrointestinal disease are at an increased risk of nutritional deterioration due to fasting for the diagnostic tests, therapeutic dietary restriction, and loss of appetite due to anorexia or altered nutritional requirement which is caused due to the disease itself. Enteral medical nutrition is preferred for the gastrointestinal disease patients as these patients cannot consume food orally and therefore enteral route is preferred to provide the required nutrients. Therefore, the growing prevalence of gastrointestinal diseases, especially in developing countries, drives the growth of the enteral medical nutrition market.
On the contrary, complications of enteral nutrition hurdle the growth of North America enteral medical nutrition market.
- Based on indication, the North America enteral medical nutrition market is segmented into respiratory disorders, cancer, post COVID-19, gastrointestinal disorders, liver failure, and others. Respiratory disorders held 40.6% market share in 2022, amassing US$ 1,461.02 million. It is projected to garner US$ 2,009.47 million by 2028 to expand at 5.5% CAGR during 2022–2028.
- Based on nutrition type, the North America enteral medical nutrition market is segmented into supplemental and sole source. The supplemental segment held 79.4% market share in 2022, amassing US$ 2,859.65 million. It is projected to garner US$ 3,943.10 million by 2028 to expand at 5.5% CAGR during 2022–2028.
- Based on form, the North America enteral medical nutrition market is segmented into powder, liquid, and semi-solid. The semi-solid segment held 48.7% market share in 2022, amassing US$ 1,754.04 million. It is projected to garner US$ 2,513.24 million by 2028 to expand at 6.2% CAGR during 2022–2028.
- Based on product, the North America enteral medical nutrition market is segmented into standard protein diet, high protein diet, fruit juice based oral nutrition, and others. The standard protein diet segment held 50.9% market share in 2022, amassing US$ 1,833.74 million. It is projected to garner US$ 2,542.89 million by 2028 to expand at 5.6% CAGR during 2022–2028.
- Based on distribution channel, the North America Enteral Medical Nutrition market is segmented into Hospital Pharmacies, Retail Stores and Other Pharmacies. The Hospital pharmacies segment held 59.2% market share in 2022, amassing US$ 2,134.17million. It is projected to garner US$ 2,924.03 million by 2028 to expand at 5.4% CAGR during 2022–2028.
- Based on Age Group, the North America enteral medical nutrition market is segmented into child (till 18 years) and adults (above 18 years). With 85.0% share of the domain, the adults segment dominated the market in 2022. It accrued US$ 3,062.17 million in 2022 and is estimated to generate US$ 4,250.02 million by 2028 to grow at a CAGR of 5.6% over the forecast period.
Our regional analysis states that the US captured 84.8% market share in 2022. It was assessed at US$ 3,053.94 million in 2022 and is likely to hit US$ 4,242.10 million by 2028, exhibiting a CAGR of 5.6% during the forecast period.
Key players dominating the North America enteral medical nutrition market are Abbott Laboratories; B. Braun Melsungen AG; DSM Nutritional Products AG; Fresenius Kabi AG; Global Health Products, Inc.; Hormel Foods Corporation; Meiji Holdings Co., Ltd.; Nestlé S.A.; Nutricia; and Smartfish AS among others.
Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com